We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16.00 | 0.98% | 1,652.00 | 1,651.50 | 1,652.50 | 1,656.00 | 1,635.00 | 1,642.00 | 1,022,365 | 11:00:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.72 | 67.62B |
From Apr 2019 to Apr 2024
LONDON--Oxford Biomedica PLC (OXB.LN), a gene and cell therapy group, on Wednesday announced that GlaxoSmithKline PLC (GSK.LN) has exercised an option to obtain a non-exclusive license for two rare orphan disease indications under Oxford BioMedica's LentiVector platform technology patents.
This follows an agreement signed between GSK and the group in December 2013.
Shares at 0803 GMT flat at 6.5 pence.
-Write to Jana Simmons at jana.simmons@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 28, 2015 04:19 ET (08:19 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
